The popularity of Medlab Middle East continued to soar, with HymonBio’s booth at the center of attention.
As the exhibition progressed steadily, it became the focus of the whole venue. Its performance is excellent: With only one tube of blood, the test can efficiently detect 28 common cancers, making the early screening process more convenient and significantly improving screening efficiency. Relying on the Q-PCR platform, it can conduct in-depth analysis of methylation and mutations of more than 400 genes. With its accurate test results, every test is more authoritative and reliable.
On this day, HymonBio worked hard and had in-depth discussions with many medical companies and reached several preliminary consensus in products, technicality, and other aspects.
The excitement continues for two more days. HymonBio awaits your visit at Z3. G18!
Post time: Feb-05-2025